The Epilepsy Research Institute – the world’s first national research institute dedicated to epilepsy – has announced the appointment of Dr John Williams as its new Chief Scientific Officer.
With extensive experience of leading collaborations to deliver globally impactful research which attracts inward investment, John will play a pivotal role in shaping and implementing the Institute’s research strategy to radically advance epilepsy research for the 1 in 100 people affected by the condition.
John joins the team with a wealth of senior leadership experience across the science and research sectors. He also has extensive experience within the biomedical R&D landscape and brings a deep understanding of research and innovation policy to his role as Chief Scientific Officer.
Epilepsy Research Institute Chief Executive, Rosemarie Pardington, said: “This appointment represents a major step forward in our mission to drive ambitious change and make a tangible difference to people’s lives through advancing epilepsy research. John’s expertise in securing and developing strategic partnerships will be instrumental in accelerating the growth and impact of the Institute’s research program. Having John as part of the leadership team will also be critical in influencing policy and practice at all levels.”
John Williams said: “I am excited to join the team and committed to building on the ground breaking work of the Epilepsy Research Institute so far. As we work to deliver an ambitious strategy, I am also keen to reflect the diversity of our stakeholders, including those living with epilepsy. Through the creation of purpose-led coalitions and a focus on shared outcomes, we have a real opportunity to drive significant progress in epilepsy research.”
The Epilepsy Research Institute was formed in October 2023 and serves as the central hub for the epilepsy research community. Its aim is to increase our understanding of the causes, prevention and treatment of epilepsy and associated conditions. The Institute is strengthening the epilepsy research ecosystem by driving strategic investment and developing partnerships and collaborations between academia, the NHS, industry, funders, patient groups and people affected by epilepsy.
The research priorities of people affected by epilepsy are central to the Institute, whose operating model is underpinned by six key research themes – Neurodevelopment, Advanced Therapeutics & Disease Modification, Mortality, Morbidity & Risk, Reproduction & Hormones, Capacity Building and Enabling Technologies. This research program aims to secure large-scale investment to radically advance research into epilepsy.